BioSpace News Archive

International medical imaging IT and cybersecurity company Sectra has installed a region-wide cloud service for the radiology and clinical physiology operations in one of Sweden’s healthcare regions, Region Västernorrland.

Vectron Biosolutions, upstream experts providing expression tools and services in biomanufacturing, announced it has raised $2.7 million in a Series A financing round led by Dynamk Capital as well as the acquisition of a bacterial secretion platform from Utah based T3S Technologies.

Merck announced that Dr. Dean Li, executive vice president and president, Merck Research Laboratories, is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series with Senior Management to discuss Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation on June 22, 2021, at 9:00 a.m. EDT.

Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced the grant recipients of its second annual Real Impact community support initiative.

Geneva, Switzerland,June17, 2021 – Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2021 Annual General Meeting.

The small-bore connectors market is pacing on account of escalated measures to prevent medical device misconnections in healthcare settings.

Scanning probe microscopes include imaging technologies that measure surface of small molecules, atoms and fine scales.

Pyrogens are substances that lead to causing fever after administration of an injection. Rise in the body temperature and body ache are some of the prominent reactions that are caused because of injection of these harmful pyrogens in the human body.

Ebola has emerged as a major hazard to mankind in recent years. Though the Ebola virus and the disease caused by it have been familiar to science for decades, the risk of a global epidemic has increased massively due to the advances in globalization.

Tiziana Life Sciences plc announces that it has submitted a grant to the United Kingdom COVID Therapeutics Advisory Panel to support further clinical development of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, as an innovative ‘Take Home’ approach for treatment of non-hospitalized patients with COVID-19.